Orthofix Strengthens Board Alignment with Major Director Stock Grant

Rhea-AI Filing Summary

Michael Finegan, Director at Orthofix Medical, reported acquiring 26,087 deferred stock units (DSUs) on June 18, 2025. The DSUs were granted at $0 and will fully vest on the first anniversary of the grant date, contingent on Finegan's continued service.

Following this transaction, Finegan beneficially owns a total of 57,391 securities, which includes:

• 26,087 newly granted DSUs
• 29,718 previously reported DSUs
• 1,586 shares acquired through Orthofix's Stock Purchase Plan on April 30, 2025

The DSUs represent a contingent right to receive one share of common stock each, with settlement occurring within 45 days of Finegan's termination of service with Orthofix. This Form 4 filing was submitted by attorney-in-fact J. Andres Cedron on June 23, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finegan Michael

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TX 75056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		26,087(1)	A	$0	57,391(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.

2. Includes 29,718 previously reported deferred stock units and 1,586 shares acquired under Orthofix's Stock Purchase Plan on 4/30/2025.

	/s/ J. Andres Cedron, attorney-in-fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many OFIX shares did Director Michael Finegan acquire on June 18, 2025?

Director Michael Finegan acquired 26,087 deferred stock units (DSUs) on June 18, 2025. Each DSU represents a contingent right to receive one share of Orthofix common stock.

What is the vesting schedule for Michael Finegan's OFIX stock units granted in June 2025?

The deferred stock units vest in full on the first anniversary of the grant date (June 18, 2026), subject to Finegan's continued service through that date. The vested units will settle and convert to common stock within 45 days after his termination of service with Orthofix.

What is the total amount of OFIX shares beneficially owned by Michael Finegan after the June 2025 transaction?

Following the transaction, Michael Finegan beneficially owned 57,391 shares, which includes 29,718 previously reported deferred stock units, 1,586 shares acquired through Orthofix's Stock Purchase Plan on April 30, 2025, and the newly granted 26,087 DSUs.

What was the purchase price for OFIX shares acquired by Michael Finegan in the June 2025 grant?

The deferred stock units were granted at $0 cost to Michael Finegan as part of his director compensation package.